#USA #San Francisco #Field Medical #FieldForce #Ablation System

Field Medical to Present at the J.P. Morgan Healthcare Conference

Field Medical Inc., a pioneering clinical-stage medical technology firm, is poised to make an impactful presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The event will take place at The Westin St. Francis in San Francisco, and the company's founder, Dr. Steven Mickelsen, will be sharing valuable insights starting at 10 a.m. PT.

The centerpiece of the presentation will be Field Medical's FieldForce™ Ablation System, an advanced pulsed field ablation (PFA) platform. This innovative device is engineered with the capability to treat complex cardiac arrhythmias, specifically ventricular tachycardia (VT) and atrial fibrillation (AF). According to Dr. Mickelsen, this system represents a significant advancement in cardiac care, promising to enhance treatment outcomes for patients suffering from these conditions.

With a focus on transmural lesion creation, the FieldForce™ system employs proprietary FieldBending™ energy technology that aims to deliver efficient and precise ablation. This groundbreaking approach is part of Field Medical’s commitment to improve the lives of patients who battle arrhythmias. During the presentation, the audience can expect a comprehensive overview of the company's progress, including details about the Field-PULSE AF study and strategic plans for the upcoming pivotal VT trial.

In addition to the presentation, Field Medical's executive team will be available for in-depth discussions and meetings throughout the conference. Those interested in arranging a meeting are encouraged to reach out via email. Dr. Mickelsen's presentation marks a crucial opportunity for professionals in the healthcare industry to learn more about emerging technologies in cardiac treatment during this prestigious event.

Background on Field Medical Inc.

Founded in 2022, Field Medical is devoted to revolutionizing cardiac treatment through innovative medical technology. As a clinical-stage company, it targets pulsed field ablation solutions for complex cardiac arrhythmias. The FieldForce™ Ablation System synergizes cutting-edge design with a focus on delivering safe and effective ablation therapies. Recently, in 2024, the system received Breakthrough Device Designation from regulatory bodies, also participating in the FDA TAP Pilot Program for ventricular tachycardia treatment.

In October 2025, the VCAS trial findings were published in Circulation, marking another milestone for Field Medical in the field of clinical research and cardiac health. As they gear up for their presentation at the J.P. Morgan Healthcare Conference, the potential for their technology to reshape arrhythmic treatment is considerable.

For updates and detailed information, Field Medical encourages interested parties to visit their official website at www.fieldmedicalinc.com and to follow them on social media platforms such as LinkedIn, X, and YouTube. The FieldForce™ Ablation System remains an investigational device, exclusively available for research purposes in accordance with federal regulations.

Important Contact Information

For media inquiries, please contact Holly Windler at 619.929.1275 or [email protected]. To reach out concerning investor relations, send an email to [email protected]. Field Medical Inc. is dedicated to bringing transformative healthcare solutions to the forefront of modern medicine.